Clinical trial results for
early-stage non-small cell lung cancer (NSCLC) before and after surgery
Given before and after surgery to adults with non-small cell lung cancer to help prevent it from returning after surgery
Actor portrayals.
An FDA-approved combination of immunotherapy and chemotherapy before surgery and immunotherapy alone after surgery that helped reduce the risk of cancer spreading or returning compared to chemotherapy alone before surgery.
This pre-surgery and post-surgery immunotherapy treatment may offer you an additional way to treat your condition. Before surgery, these treatments help shrink tumors. After surgery, they attack cancer cells that may remain “hidden” or hard to see and aim to keep them from coming back.
About the clinical trial
In a clinical trial of 461 people with early-stage NSCLC who were able to have surgery, 229 people were given OPDIVO + chemotherapy before surgery followed by OPDIVO alone after surgery, and 232 people were given platinum-based chemotherapy before surgery followed by placebo after surgery.
More people given the OPDIVO-based treatment did not have their cancer return or spread compared to chemotherapy alone at a minimum follow-up of 16 months
OPDIVO + chemotherapy and OPDIVO alone will not work for everyone. Individual results may vary.
Getting treatment
See treatment plans and what to expect from an intravenous (IV) infusion or under-the-skin injection (subcutaneous injection)
For adults with early-stage non-small cell lung cancer (NSCLC) before and after surgery
As an intravenous infusion
OPDIVO® (nivolumab) is a prescription medicine used in combination with chemotherapy that contains platinum and another chemotherapy medicine before you have surgery for early-stage NSCLC that does not have an abnormal EGFR or ALK gene, and then may be continued alone after surgery to help prevent your lung cancer from coming back.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.
As a subcutaneous injection
OPDIVO Qvantig™ (nivolumab + hyaluronidase-nvhy) is a prescription medicine used in combination with chemotherapy that contains platinum and another chemotherapy medicine, before you have surgery, for adults with early stage lung cancer (called non-small cell lung cancer) that does not have an abnormal EGFR or ALK gene and then may be continued alone after surgery to help prevent your lung cancer from coming back.
It is not known if OPDIVO Qvantig is safe and effective in children.